Sonidegib phosphate is under clinical development by Sun Pharma Advanced Research and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Sonidegib phosphate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sonidegib phosphate overview
Sonidegib phosphate (Odomzo) is an anticancer agent. It is formulated as a hard gelatin capsules for oral route of administration. Odomzo is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
It is under development for the treatment of adenocarcinoma of the gastroesophageal junction and newly diagnosed medullablastoma. It was under development for the treatment of acute lymphocytic leukemia, acute myelocytic leukemia, child-pugh A cirrhosis, pancreatic adenocarcinoma, platinum-resistant or refractory or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma, myelofibrosis, post essential thrombocythemia myelofibrosis, post polycythemia vera myelofibrosis, adenocarcinoma of esophagus or gastroesophageal junction, extensive stage small-cell lung cancer, advanced or metastatic hepatocellular carcinoma, relapsed or refractory multiple myeloma, Gorlin syndrome, sporadic superficial nodular skin basal cell carcinomas, medulloblastoma, solid tumor, hematologic malignancies and chronic myelocytic leukemia, hedgehog pathway-mutated myelodysplastic syndrome, recurrent glioblastoma multiforme, estrogen receptor negative and HER2 negative breast cancer, metastatic colorectal cancer, castration-resistant prostate cancer, steroid-refractory chronic graft versus host disease (GVHD) after allogeneic HSCT.
Sun Pharma Advanced Research overview
Sun Pharma Advanced Research (SPARC), a subsidiary of Shanghvi Finance Pvt Ltd, is a biopharmaceutical clinical research and development service provider. The company develops active pharmaceutical ingredients, formulations and drug delivery technologies for the treatment of cancer and inflammatory diseases. Its research category consists of therapeutic focus, delivery technologies, research programs and research and development pipeline. SPARC’s therapeutic focus comprises oncology, neurodegeneration, ophthalmology, dermatology and abuse-deterrent formulations. The company’s research and development pipeline includes levetiracetam ER, latanoprost BAK Free, salmeterol-fluticasone DPI, baclofen GRS, PICN, brimonidine OD, SDN – 021, SUN – K0706, SUN – 597 Topical, SUN – K0706, minocycline topical, SUN – K0954 and SDP – 037. SPARC is headquartered in Mumbai, Maharashtra, India.
For a complete picture of Sonidegib phosphate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
